Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03889288
Other study ID # 38RC18.170
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 16, 2019
Est. completion date January 2022

Study information

Verified date February 2021
Source University Hospital, Grenoble
Contact Pierre Albaladejo, MD, PhD
Phone +33 4 76 76 92 88
Email palbaladejo@chu-grenoble.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate a new medical device in the management of pain. The principle of this new treatment is based on the emission of electromagnetic radiation in millimeter band. This new modality of pain management is evaluated in a perioperative management in patients undergoing surgery for aortic valve replacement. The hypothesis is that the use of this medical device in perioperative would reduce the consumption of postoperative morphine with an identical quality of analgesia. The decline in morphine consumption would allow a decrease in opioid adverse effects.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date January 2022
Est. primary completion date January 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - candidate for an aortic valve replacement with extra-corporal flow. - wrist size between 14.5 and 18.5 centimeters (for the experimental group) - patient affiliated to social security - signature of the informed consent (for the experimental group) Exclusion Criteria for the control group : - patient with diabetes - patient with an evolutive cancer - patient with cardiac assistance - patient under the influence of opioid in the 48 hours before the surgery - patient deprived of liberty by judicial or administrative decision - patient subject to legal protection or unable to express his consent (guardianship or curators) Exclusion Criteria for the experimental group : - patient with diabetes - patient with an evolutive cancer - patient with surgery planning within 48 hours - patient with cardiac assistance - patient under the influence of opioid in the 48 hours before the surgery - patient suffering from a dermatological disease such as oozing dermatitis, hyper sweating, or an unhealed lesion in the wrists. - patient who has a piercing in the wrist or another metal material - patient known for having a multi-resistant bacterial strain - protected person referred to in Articles L1121-5 to L1121-8 of the Code of Public Health - exclusion period of another interventional study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Medical device - electronic-pain killer
Treatment sessions with the medical device (no-marked EC): 2 sessions before surgery and 4 or 5 sessions until 48 hours after surgery. Each treatment sessions takes 45 minutes. Each session is spaced by 12 +/-3 hours.

Locations

Country Name City State
France Grenoble Alpes University Hospital Grenoble

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Grenoble Clinical Investigation Centre for Innovative Technology, Remedee Labs SAS

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative consumption of morphine auto-administered in the experimental group in the first 48 hours : descriptive analysis The morphine cumulative consumption administered by auto-analgesia in the experimental group at 24 and 48 hours after the surgery 48 hours
Secondary Cumulative consumption of morphine auto-administered in the control group in the first 48 hours : descriptive analysis The morphine cumulative consumption administered by auto-analgesia in the control group at 24 and 48 hours after the surgery 48 hours
Secondary Determine the number of patients required to demonstrate a 30% decrease in morphine consumption within the first 48h following aortic valve replacement surgery in a population treated with "Electronic-Pain-Killer" compared to conventional pain management Cumulative morphine consumption in milligrams, administered by auto-analgesia, at 48 hours post-operatively in the experimental and control groups. 48 hours
Secondary Troponin's peak characterization in the first 48 hours postoperatively. The troponin is assessed in ng/ml in the two groups from the end of the surgery until 48 hours postoperatively 48 hours
Secondary The Pain characterization: Echelle Numérique Standard; standard digital scale The patient pain is evaluated using the ENS (Echelle Numérique Standard; standard digital scale, score between 0 to 10) for both groups. 48 hours
Secondary The hospitalization length in the intensive care unit For the two groups, the hospitalization length in the intensive care unit is assessed in hours. 48 hours
Secondary Characterization of analgesic drugs The analgesic drugs are characterized by their class, dose and number of dose taken in the two groups since they are in the intensive care unit. 48 hours
Secondary Number of postoperative nausea or vomiting events (number of PONV) in the experimental group In the experimental group, the number of PONV events requiring a treatment is assessed. 48 hours
Secondary Delirium events in the experimental group The number of delirium events is assessed using the CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) scale in the experimental group. 48 hours
Secondary Adverse effect from the medical device The number of adverse effects from the medical device is assessed from the first session with the medical device to the follow-up visit. 48 hours
Secondary Description of the medical device use Log files of the medical device are extracted. The length of each session, the start and end session times, each stopping is analysed. 48 hours
Secondary Medical device acceptability : score This score has been specifically created for the electronic pain killer medical device. Each item range from 0 (the worst) to 10 (the best). 48 hours
Secondary Medical device acceptability : descriptive analysis Open questions will be asked in a questionnaire without scale. A descriptive analysis will be done with the answers. 48 hours
Secondary Use Error evaluation : System Usability Scale (SUS) The System Usability Scale (SUS) contains 10 questions that are rated on a scale from 1 to 5. "The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100." Jeff Sauro established the average score of SUS is 68.
The score can go from 0 (worst) to 100 (best).
48 hours
Secondary Subgroup analysis excluding patients who have had Nefopam administration To avoid a potential bias confusion, patients taking Nefopam drug are excluded from the analyses and all the previous outcome are assessed again. 48 hours
See also
  Status Clinical Trial Phase
Completed NCT00774293 - Homoeopathic Association in Aortic Valve Surgery Phase 4
Completed NCT05107453 - Serratus Anterior Plane Block for Minimal Invasive Cardiac Surgery Phase 4
Completed NCT01651780 - Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH Phase 3
Completed NCT01187329 - The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose N/A
Recruiting NCT05295628 - Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR N/A
Terminated NCT03680040 - RESILIENCE Trial: Evaluation of the Durability of Aortic Bioprostheses/Valves With RESILIA Tissue in Subjects Under 65
Recruiting NCT05539937 - Prospective Evaluation of the Quality of Life of Elderly Patients Undergoing Transfemoral Percutanous Aortic Valve Replacement (TAVI) for the Treatment of Severe Aortic Stenosis.
Recruiting NCT01522352 - Comparison Between Three Types of Stented Pericardial Aortic Valves N/A
Completed NCT01554709 - Safety and Performance Study of the CardioGard Cannula Phase 2/Phase 3
Suspended NCT04902053 - INSPIRIS RESILIA Aortic Valve, Valve-in-Valve Surveillance Study
Completed NCT01404975 - TAVI Protocol - Paravertebral Block Study N/A
Active, not recruiting NCT05404880 - INSPIRIS China PMCF Study
Recruiting NCT04652375 - Outcomes After Albumin vs Lactated Ringer's Solution in CABG and AVR Procedures N/A
Recruiting NCT06106451 - Optimization Post-TAVR to IMprove Activity Levels (OPTIMAL Study) N/A
Completed NCT00860730 - PERCEVAL Pivotal Trial N/A
Active, not recruiting NCT00396760 - Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery Phase 3
Not yet recruiting NCT03603483 - Aortic Root Enlargement in Aortic Valve Replacement N/A
Terminated NCT01368666 - Safety and Effectiveness Study of Perceval S Valve for Extended CE Mark N/A
Recruiting NCT03002272 - Transcatheter Aortic Prosthesis Function: A Long-term Follow-up Study
Active, not recruiting NCT03258333 - Small Aortic Annulus - a New Solution to the Old Problem N/A